⌂
Home
◈
Markets
▦
Screener
📈
Tools
◎
Portfolio
Skip to content
DFM General
5,823.50
−0.19%
FTSE ADX
9,790.47
−0.40%
TASI
9,952.06
−1.69%
QE Index
8,658.85
+0.70%
S&P 500
7,712.57
+0.28%
Nasdaq 100
29,490.28
−0.13%
Nifty 50
22,704.40
−0.81%
Sensex
73,360.48
−0.67%
KSE-100
165,671.54
+0.31%
DFM:EMIRATESNBD
AED 31.60
+0.06%
ADX:IHC
AED 353.80
−0.79%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.54
−0.06%
NAS:NVDA
$216.47
−0.29%
NYSE:TSM
$425.08
+1.16%
NSE:RELIANCE
₹1,209.60
+0.63%
KAR:OGDC
Rs 300.48
+0.16%
Gold
$4,114.39
−0.27%
Brent
$110.16
+0.98%
BTC
$82,671.58
−0.33%
ETH
$2,438.72
−0.33%
DFM General
5,823.50
−0.19%
FTSE ADX
9,790.47
−0.40%
TASI
9,952.06
−1.69%
QE Index
8,658.85
+0.70%
S&P 500
7,712.57
+0.28%
Nasdaq 100
29,490.28
−0.13%
Nifty 50
22,704.40
−0.81%
Sensex
73,360.48
−0.67%
KSE-100
165,671.54
+0.31%
DFM:EMIRATESNBD
AED 31.60
+0.06%
ADX:IHC
AED 353.80
−0.79%
SAU:2222
SAR 25.48
−1.24%
DSMD:QNBK
QAR 15.54
−0.06%
NAS:NVDA
$216.47
−0.29%
NYSE:TSM
$425.08
+1.16%
NSE:RELIANCE
₹1,209.60
+0.63%
KAR:OGDC
Rs 300.48
+0.16%
Gold
$4,114.39
−0.27%
Brent
$110.16
+0.98%
BTC
$82,671.58
−0.33%
ETH
$2,438.72
−0.33%
☰
Markets
▼
Stock markets
🇦🇪
UAE
DFM · ADX · DFM General
Open
🇸🇦
Saudi Arabia
Tadawul · TASI
Open
🇶🇦
Qatar
QSE · QE General
Open
🇺🇸
United States
Nasdaq · NYSE · S&P 500
Closed
🇮🇳
India
NSE · BSE · Nifty 50
Open
🇵🇰
Pakistan
PSX · KSE-100
Open
Other assets
₿
Crypto
Ranked by volume · 24/7
🥇
Gold, FX & economy
Dubai gold, AED crosses, rates
◫
ETFs
Index, sector and gold funds
Explore
▦
Market map
Every market as a heatmap
📅
Calendar & IPOs
Earnings, dividends, listings, releases
⌁
Options flow · Ownership · Politics
US filings and tapes
Screener
▼
⚲
Stock screener
All six markets, one row per company
★
Ready-made screens
Starting points with a point of view
📁
My saved screens
Saved rules with alerts on new matches
⇄
Compare
Up to five, side by side
Crypto
Tools
▼
📈
Charting
Drawings, indicators, replay
▶
Strategy Maker
Write a rule, test it on history
⇄
Compare
Side by side
🔔
Alerts
Price, earnings, screens, strategies
News
Portfolio
⌕
AED
USD
SAR
QAR
INR
PKR
GBP
EUR
KWD
OMR
BHD
☆
♢
☾
Sign in
Create account
👤
Markets
›
United States
› NAS
› JBIO
J
Jade Biosciences Inc
NAS:JBIO
Healthcare
CBOEFTSE:MRUT
NASDAQ:NQUSSG
$14.77
+6.80%
Live
In session · ≈
AED 54.24
· Market cap
$939.33M
· Next earnings
Thu 12 Nov
☆
Watch
🔔
Alert
⇄
Compare
▶
Test a strategy
✦
AI read
Overview
Chart
Financials
Valuation
Forecasts
Dividends
Ownership
Options
Shorts
News
Profile
Jade Biosciences Inc · News · TradingHolo
JBIO news
Headlines tagged to this company
DO
Jade Biosciences Price Target Maintained With a $47.00/Share by Wedbush
Dow Jones Newswires · 20 d ago
TR
Wedbush reiterates Outperform rating on Jade Biosciences, $47 price target
TradingView · 20 d ago
DO
Jade Biosciences Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
Dow Jones Newswires · 20 d ago
TR
HC Wainwright & Co. reiterates Buy rating on Jade Biosciences, $55 price target
TradingView · 20 d ago
QU
JBIO: JADE301 preclinical data support best-in-class potential for DM with subcutaneous dosing
Quartr · 21 d ago
QU
JBIO: JADE301 shows best-in-class preclinical profile for dermatomyositis, with phase I starting Q4 2026
Quartr · 21 d ago
QU
JBIO: Advancing three novel autoimmune therapies with strong clinical progress and major milestones ahead
Quartr · 21 d ago
QU
JBIO: JADE301 enters Phase 1 for dermatomyositis, showing superior preclinical potency and dosing profile
Quartr · 21 d ago
TR
Jade Bios reports potent preclinical JADE301 data, 30-day NHP half-life and Phase 1 start planned
TradingView · 21 d ago
QU
JBIO: JADE301 demonstrated potent, selective IFN-β inhibition and strong safety, with Phase 1 trials planned
Quartr · 21 d ago
RE
Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
Reuters · 21 d ago
GL
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
GlobeNewswire · 21 d ago
GL
Jade Biosciences to Participate in Upcoming Conferences
globenewswire · 50 d ago
SE
Jade Biosciences: Duration Is The Real Product
Seeking Alpha · 63 d ago
GL
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
GlobeNewsWire · 73 d ago
End of the feed